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Background:  Restenosis after femoropopliteal (FP) stenting remains a significant clinical problem. We investigated whether cilostazol would 
reduce restenosis in patients after stent implantation for FP disease.
Methods:  This study was a multicentre retrospective analysis. From April 2004 to December 2009, 1085 lesions (1062 limbs and 861 patients, 
mean age 72 years, 31% female and lesion length 143mm) who underwent successful FP stenting with nitinol stent for de novo lesions were enrolled 
and divided into two groups: patients who received cilostazol (n=633) and didnot received cilostazol (n=452). Primary patency was defined as a 
treated lesion without restenosis (>2.4 of peak systolic velocity ratio by duplex or >50% stenosis by angiogram). Secondary patency was defined as 
a target vessel that subsequently became totally occluded. Outcome measures of this study were primary patency, secondary patency and all-cause 
mortality.
Results:  Mean follow-up period was 24 months. Kaplan-Meier analysis demonstrate primary and secondary patency at 6-year was significantly 
higher in cilostazol group (66.9 vs. 54.0%, p<0.0001 and 89.1 vs. 81.5%, p=0.005, respectively). No significant difference on survival was found 
between both groups (78.0 vs.74.7%, p=0.43). On multivariate analysis, cilostazol, stent fracture, hemodialysis and TASCII C/D were the independent 
predictors of primary patency.
Conclusions:  Cilostazol improved primary patency after successful FP stenting with nitinol stent. 
